AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34254537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention for dietary and lifestyle modification for 3 months
Number of subjects: 120
Study 34254537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 36155502 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 32
Study 36155502 — intervention group
Group type: COMPARATOR
Intervention: Balance and tone training (control)
Number of subjects: 32
Study 33493028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 33493028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study 33493028 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence algorithm
Number of subjects: 0
Study 33493028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 0
Study 33493028 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 18F-sodium florid activity
Number of subjects: 0
Study 32703201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 90
Study 32703201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 90
Study 36354040 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3437943 3 mg
Number of subjects: 72
Study 36354040 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3437943 3/6 mg
Number of subjects: 72
Study 36354040 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3437943 3/6/9/12 mg
Number of subjects: 72
Study 36354040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 36354040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 72
Study 36354040 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3437943
Number of subjects: 72
Study 33961863 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation to the dorsomedial prefrontal cortex (dmPFC)
Number of subjects: 69
Study 33961863 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 69
Study 33961863 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation to the right temporoparietal junction (rTPJ)
Number of subjects: 69
Study 32739150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCT reconstructions with subtraction of unfractured bones
Number of subjects: 20
Study 32739150 — intervention group
Group type: COMPARATOR
Intervention: 3DCT reconstructions without subtraction of unfractured bones
Number of subjects: 20
Study 32739150 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for non-trauma surgeons
Number of subjects: 20
Study 32739150 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for fracture characteristics
Number of subjects: 20
Study 35579350 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Number of subjects: 101
Study 35579350 — intervention group
Group type: COMPARATOR
Intervention: Custodiol
Number of subjects: 101
Study 33605791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 6914
Study 33605791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6914
Study 34414678 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily for 8 weeks
Number of subjects: 44
Study 34414678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32730985 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC+allograft
Number of subjects: 73
Study 32730985 — intervention group
Group type: COMPARATOR
Intervention: AICBG
Number of subjects: 73
Study 32730985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 35860804 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 34490493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic [18F]FET PET radiomics (TTP model)
Number of subjects: 159
Study 34490493 — intervention group
Group type: EXPERIMENTAL
Intervention: Early static [18F]FET PET radiomics (TBR5-15 model)
Number of subjects: 159
Study 34490493 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard static [18F]FET PET radiomics (TBR20-40 model)
Number of subjects: 159
Study 35143622 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by observation in responding patients
Number of subjects: 53
Study 35143622 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by bortezomib maintenance in responding patients
Number of subjects: 53
Study 35143622 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring after induction
Number of subjects: 53
Study 35143622 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA dynamics assessment during the bortezomib window
Number of subjects: 53
Study 35143622 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA negativity after induction
Number of subjects: 53
Study 35017939 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (extraction of contralateral premolars on the 28th day after bonding)
Number of subjects: 40
Study 35017939 — intervention group
Group type: COMPARATOR
Intervention: Control group (extraction of permanent first premolars on day 1 of bonding)
Number of subjects: 40
Study 33788452 — intervention group
Group type: EXPERIMENTAL
Intervention: Governor Vessel moxibustion therapy, applied once a week for 8 weeks.
Number of subjects: 100
Study 33788452 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin calcium tablets (10 mg) once daily for 8 weeks (Control).
Number of subjects: 100
Study 33788452 — intervention group
Group type: COMPARATOR
Intervention: Governor Vessel moxibustion therapy (I) vs Atorvastatin (C) for CAS clinical effect.
Number of subjects: 100
Study 33010491 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (19 common invasive procedures)
Number of subjects: 183430
Study 33010491 — intervention group
Group type: COMPARATOR
Intervention: Control group (10% random sample of non-surgical patients)
Number of subjects: 183430
Study 33340853 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX with continuous oxaliplatin (8 cycles of CAPOX)
Number of subjects: 200
Study 33340853 — intervention group
Group type: COMPARATOR
Intervention: CAPOX with intermittent oxaliplatin (2 cycles of CAPOX, 4 cycles of capecitabine, and 2 cycles of CAPOX)
Number of subjects: 200
Study 32543150 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 24
Study 32543150 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid®
Number of subjects: 24
Study 35989940 — intervention group
Group type: EXPERIMENTAL
Intervention: USL (digital therapeutic app)
Number of subjects: 98
Study 35989940 — intervention group
Group type: COMPARATOR
Intervention: WN (White Noise Lite app)
Number of subjects: 98
Study 33883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability, prescribed at 3 sessions per week for 4 or 6 weeks.
Number of subjects: 0
Study 33883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability with coaching and individualized progressions.
Number of subjects: 0
Study 33883300 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs targeting scapular kinematics and stability.
Number of subjects: 0
Study 34130213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 34
Study 34130213 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 35734953 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow yeast rice (YYR)
Number of subjects: 58
Study 35734953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34374529 — intervention group
Group type: EXPERIMENTAL
Intervention: ssDNA triplex-forming oligos (TFOs) at pH 5
Number of subjects: 67000000
Study 34374529 — intervention group
Group type: EXPERIMENTAL
Intervention: ssDNA triplex-forming oligos (TFOs) at pH 7
Number of subjects: 67000000
Study 34374529 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplex-forming motifs (TFMs) identified from the oligo library
Number of subjects: 67000000
Study 34374529 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-variant verification experiments with TFOs containing TFMs
Number of subjects: 67000000
Study 36310890 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-directed video instruction module
Number of subjects: 99
Study 36310890 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led traditional classroom instruction module
Number of subjects: 99
Study 33434629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic very low calorie diet (VLCD), video consultations, educational resources
Number of subjects: 24
Study 36164012 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB) 200 mg QD
Number of subjects: 130
Study 36164012 — intervention group
Group type: COMPARATOR
Intervention: Danazol (DAN) 600 mg QD
Number of subjects: 130
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose right unilateral ECT (6 × seizure threshold)
Number of subjects: 61
Study 34033117 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal ECT (1.5 × seizure threshold)
Number of subjects: 61
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 61
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic features at pre-ECT baseline
Number of subjects: 61
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of previous depressive episodes
Number of subjects: 61
Study 34033117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar II diagnosis
Number of subjects: 61
Study 33574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 1
Number of subjects: 261647
Study 33574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 2
Number of subjects: 261647
Study 33574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model for predicting intradialytic hypotension 3
Number of subjects: 261647
Study 33574056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network model
Number of subjects: 261647
Study 36480346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program combined with music therapy
Number of subjects: 120
Study 32931612 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 units of vitamin E/day
Number of subjects: 91
Study 32931612 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of vitamin C/day
Number of subjects: 91
Study 32931612 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 units of vitamin E and 1,000 mg of vitamin C/day
Number of subjects: 91
Study 32931612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 32640132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab (60 mg subcutaneously every 4 weeks)
Number of subjects: 215
Study 32640132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously every 4 weeks)
Number of subjects: 215
Study 32640132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Number of subjects: 215
Study 32640132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 36517320 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined pediatric anxiety program (six lessons, 20-30 minutes each)
Number of subjects: 0
Study 32800029 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily inhalation of budesonide 200 μg/day
Number of subjects: 120
Study 32800029 — intervention group
Group type: COMPARATOR
Intervention: Intermittent inhalation of budesonide 200 μg/day
Number of subjects: 120
Study 32800029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 120
Study 35133884 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 16 mg/day
Number of subjects: 151
Study 35133884 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin 8 mg/day
Number of subjects: 151
Study 35133884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 33973914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging with EDTA
Number of subjects: 38
Study 33973914 — intervention group
Group type: COMPARATOR
Intervention: Conventional packaging with EDTA
Number of subjects: 38
Study 33973914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging without EDTA
Number of subjects: 38
Study 33973914 — intervention group
Group type: COMPARATOR
Intervention: Conventional packaging without EDTA
Number of subjects: 38
Study 33973914 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 38
Study 33973914 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel lenses
Number of subjects: 38
Study 33973914 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger contamination
Number of subjects: 38
Study 36095195 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime and nighttime eating during simulated night work
Number of subjects: 0
Study 36095195 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime-only eating during simulated night work
Number of subjects: 0
Study 36095195 — intervention group
Group type: COMPARATOR
Intervention: Simulated day work (baseline)
Number of subjects: 0
Study 34067524 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplement (450 mg for men, 300 mg for women)
Number of subjects: 19
Study 34067524 — intervention group
Group type: COMPARATOR
Intervention: Control (water without magnesium supplement)
Number of subjects: 19
Study 34579601 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent HIV diagnosis
Number of subjects: 824
Study 34579601 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-related stigma
Number of subjects: 824
Study 34579601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 824
Study 34579601 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support score
Number of subjects: 824
Study 34579601 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risk percent
Number of subjects: 824
Study 33306418 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab biosimilar (60 mg)
Number of subjects: 52
Study 33306418 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 52
Study 33306418 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab biosimilar
Number of subjects: 52
Study 32215798 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤ 25% pink dye effluent
Number of subjects: 28
Study 32215798 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤ 25% violet dye effluent
Number of subjects: 28
Study 32215798 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤ 10% black dye effluent
Number of subjects: 28
Study 32215798 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of heavy metals (Pb, Cr, Fe, Mn)
Number of subjects: 28
Study 32215798 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey data
Number of subjects: 28
Study 35615783 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic peanut oral immunotherapy
Number of subjects: 32
Study 35615783 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 34431258 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (OLA)
Number of subjects: 112
Study 36476455 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AZD1222) vaccine
Number of subjects: 174
Study 34134027 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Mothers and Babies Course and Early Childhood Development (iMBC/ECD)
Number of subjects: 417
Study 34134027 — intervention group
Group type: COMPARATOR
Intervention: ECD only content (Control)
Number of subjects: 417
Study 34134027 — intervention group
Group type: EXPERIMENTAL
Intervention: iMBC/ECD (for sub-group with high program attendance)
Number of subjects: 417
Study 32386476 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib plus propacetamol
Number of subjects: 0
Study 32386476 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib
Number of subjects: 0
Study 32386476 — intervention group
Group type: EXPERIMENTAL
Intervention: propacetamol
Number of subjects: 0
Study 32386476 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 33385521 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus exemestane
Number of subjects: 601
Study 33385521 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 601
Study 33385521 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 601
Study 33385521 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus ET
Number of subjects: 601
Study 32410715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive video-game training (CI) + endurance, strength, and music-movement coordination (EI)
Number of subjects: 144
Study 32410715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive video-game training (CI) + stretching, toning, and relaxation (EC)
Number of subjects: 144
Study 32410715 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games not specifically designed to train cognition (CC) + endurance, strength, and music-movement coordination (EI)
Number of subjects: 144
Study 32410715 — intervention group
Group type: EXPERIMENTAL
Intervention: Video games not specifically designed to train cognition (CC) + stretching, toning, and relaxation (EC)
Number of subjects: 144
Study 32410715 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CI or CC) + physical control activity (EC)
Number of subjects: 144
Study 32410715 — intervention group
Group type: COMPARATOR
Intervention: Physical training (EI or EC) + cognitive control activity (CC)
Number of subjects: 144
Study 32410715 — intervention group
Group type: COMPARATOR
Intervention: Combination of both control activities (CC + EC)
Number of subjects: 144
Study 35200145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (wearable device + mobile app)
Number of subjects: 221
Study 35200145 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (wearable device only)
Number of subjects: 221
Study 33308122 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingpeng ointment with routine medical treatment and rehabilitative care
Number of subjects: 120
Study 33308122 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment without Qingpeng ointment
Number of subjects: 120
Study 35548968 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid and ipidacrine hydrochloride
Number of subjects: 32
Study 35548968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 32
Study 32092208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 18
Study 32092208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 34875207 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (spherical aberration -0.27 μm)
Number of subjects: 60
Study 34875207 — intervention group
Group type: COMPARATOR
Intervention: Group B (spherical aberration -0.20 μm)
Number of subjects: 60
Study 34407826 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking therapy for depression
Number of subjects: 14
Study 34407826 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of the study team with the clinical recruitment site
Number of subjects: 14
Study 34407826 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent presence of a researcher in clinics
Number of subjects: 14
Study 32041669 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection
Number of subjects: 142
Study 32041669 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal dexamethasone implant (700 μg)
Number of subjects: 142
Study 616461890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy)
Number of subjects: 242
Study 616461890 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate diet (65% energy)
Number of subjects: 242
Study 616461890 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy), higher fat (35% energy), lower carbohydrate (45% energy)
Number of subjects: 242
Study 36225132 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone oral suspension administered orally
Number of subjects: 36
Study 36225132 — intervention group
Group type: COMPARATOR
Intervention: Edaravone oral suspension administered via nasogastric tube (NGT)
Number of subjects: 36
Study 36225132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and NGT administration
Number of subjects: 36
Study 34450361 — intervention group
Group type: EXPERIMENTAL
Intervention: Active break intervention
Number of subjects: 193
Study 34450361 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural shift intervention
Number of subjects: 193
Study 34450361 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo seat pad)
Number of subjects: 193
Study 36388825 — intervention group
Group type: EXPERIMENTAL
Intervention: External diaphragmatic pacing (EDP)
Number of subjects: 51
Study 36388825 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 51
Study 32048274 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of iv dexamethasone 24 mg
Number of subjects: 0
Study 32048274 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive doses of iv dexamethasone 24 mg
Number of subjects: 0
Study 32048274 — intervention group
Group type: COMPARATOR
Intervention: Matching iv placebo
Number of subjects: 0
Study 35666927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone disruptions
Number of subjects: 114
Study 35666927 — intervention group
Group type: COMPARATOR
Intervention: Social disruptions
Number of subjects: 114
Study 35666927 — intervention group
Group type: COMPARATOR
Intervention: Undisrupted play
Number of subjects: 114
Study 33001159 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eyedrops, 0.5%
Number of subjects: 50